SG11201508405QA - 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors - Google Patents

2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors

Info

Publication number
SG11201508405QA
SG11201508405QA SG11201508405QA SG11201508405QA SG11201508405QA SG 11201508405Q A SG11201508405Q A SG 11201508405QA SG 11201508405Q A SG11201508405Q A SG 11201508405QA SG 11201508405Q A SG11201508405Q A SG 11201508405QA SG 11201508405Q A SG11201508405Q A SG 11201508405QA
Authority
SG
Singapore
Prior art keywords
aminopyrido
wee
pyrimidin
inhibitors
derivatives
Prior art date
Application number
SG11201508405QA
Other languages
English (en)
Inventor
Colin Roderick O'dowd
James Samuel Shane Rountree
Frank Burkamp
Andrew John Wilkinson
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Publication of SG11201508405QA publication Critical patent/SG11201508405QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
SG11201508405QA 2013-04-11 2014-04-11 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors SG11201508405QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1306610.5A GB201306610D0 (en) 2013-04-11 2013-04-11 Pharmaceutical compounds
PCT/GB2014/051136 WO2014167347A1 (en) 2013-04-11 2014-04-11 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors

Publications (1)

Publication Number Publication Date
SG11201508405QA true SG11201508405QA (en) 2015-11-27

Family

ID=48537110

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201508405QA SG11201508405QA (en) 2013-04-11 2014-04-11 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors

Country Status (16)

Country Link
US (1) US9714244B2 (pt)
EP (1) EP2984090B1 (pt)
JP (1) JP6412920B2 (pt)
KR (1) KR102250668B1 (pt)
CN (1) CN105209463B (pt)
AU (1) AU2014252828B2 (pt)
BR (1) BR112015026023A2 (pt)
CA (1) CA2909365C (pt)
GB (1) GB201306610D0 (pt)
HK (1) HK1219474A1 (pt)
IL (1) IL242000B (pt)
MX (1) MX362215B (pt)
RU (1) RU2656342C2 (pt)
SG (1) SG11201508405QA (pt)
WO (1) WO2014167347A1 (pt)
ZA (1) ZA201507874B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014010176A (es) * 2012-02-23 2014-11-10 Abbvie Inc Inhibidores de cinasas de piridopirimidinona.
WO2016204429A1 (ko) * 2015-06-18 2016-12-22 한국화학연구원 헤테로아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물.
KR101845931B1 (ko) 2015-06-18 2018-04-05 한국화학연구원 헤테로아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
CN107459519A (zh) * 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
GB201612095D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
JP6717457B2 (ja) 2017-01-23 2020-07-01 シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド Wee1阻害剤としての1,2−ジヒドロ−3H−ピラゾロ[3,4−d]ピリミジン−3−オン誘導体
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
SG11201908788YA (en) 2017-03-31 2019-10-30 Seattle Genetics Inc Combinations of chk1- and wee1 - inhibitors
US20200291018A1 (en) * 2017-07-13 2020-09-17 Syros Pharmaceuticals, Inc. Tam kinase inhibitors
US11299493B2 (en) 2017-10-09 2022-04-12 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2019074981A1 (en) 2017-10-09 2019-04-18 GiraFpharma LLC HETEROCYCLIC COMPOUNDS AND USES THEREOF
SG11202003974XA (en) 2017-11-01 2020-05-28 Shijiazhuang Sagacity New Drug Development Co Ltd Macrocyclic compound serving as weel inhibitor and applications thereof
GB201800378D0 (en) * 2018-01-10 2018-02-21 Almac Discovery Ltd Pharmaceutical compounds
CN112955454A (zh) 2018-10-26 2021-06-11 石家庄智康弘仁新药开发有限公司 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用
KR20200100429A (ko) * 2019-02-18 2020-08-26 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 신규한 피리도[3,4-d]피리미딘-8-온 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
JP2022528047A (ja) 2019-03-22 2022-06-08 ショウヤオ ホールディングス(ベイジン) カンパニー, リミテッド Wee1阻害剤、その製造および用途
WO2020210375A1 (en) 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020221358A1 (zh) 2019-04-30 2020-11-05 石家庄智康弘仁新药开发有限公司 Wee1抑制剂化合物的晶型及其应用
AU2021290701A1 (en) 2020-06-17 2023-02-02 Wigen Biomedicine Technology (shanghai) Co., Ltd. Pyrazolo(3,4-d)pyrimidine-3-ketone derivative as Wee-1 inhibitor
EP4332104A1 (en) 2021-04-30 2024-03-06 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Fused ring compound as wee-1 inhibitor, and preparation method therefor and use thereof
AU2022287033A1 (en) * 2021-06-04 2024-01-18 Aprea Therapeutics, Inc. Pyridopyrimidine derivatives useful as wee1 kinase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2783B1 (en) * 2005-09-30 2014-03-15 نوفارتيس ايه جي Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones
AR060635A1 (es) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
US8383635B2 (en) * 2008-08-12 2013-02-26 Glaxosmithkline Llc Chemical compounds
BRPI0924107A2 (pt) * 2008-11-28 2019-09-24 Novartis Ag inibidores de hsp90 para tratamento terapêutico
US8575179B2 (en) 2008-12-12 2013-11-05 Msd K.K. Dihydropyrazolopyrimidinone derivatives
JP2012511502A (ja) * 2008-12-12 2012-05-24 Msd株式会社 ジヒドロピリミドピリミジン誘導体
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
EP2731953A1 (en) 2011-07-15 2014-05-21 Abbvie Inc. Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases
US8796289B2 (en) * 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
MX2014010176A (es) * 2012-02-23 2014-11-10 Abbvie Inc Inhibidores de cinasas de piridopirimidinona.

Also Published As

Publication number Publication date
US9714244B2 (en) 2017-07-25
IL242000B (en) 2021-03-25
WO2014167347A1 (en) 2014-10-16
BR112015026023A2 (pt) 2017-07-25
AU2014252828A1 (en) 2015-11-05
CA2909365C (en) 2021-11-09
JP6412920B2 (ja) 2018-10-24
RU2015148189A (ru) 2017-05-23
MX362215B (es) 2019-01-09
EP2984090A1 (en) 2016-02-17
MX2015014234A (es) 2016-06-16
US20160060258A1 (en) 2016-03-03
EP2984090B1 (en) 2017-05-31
GB201306610D0 (en) 2013-05-29
KR102250668B1 (ko) 2021-05-10
ZA201507874B (en) 2017-09-27
JP2016516763A (ja) 2016-06-09
HK1219474A1 (zh) 2017-04-07
CN105209463A (zh) 2015-12-30
CN105209463B (zh) 2017-10-13
NZ713114A (en) 2021-01-29
KR20150143668A (ko) 2015-12-23
AU2014252828B2 (en) 2018-07-05
RU2656342C2 (ru) 2018-06-05
CA2909365A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
ZA201507874B (en) 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors
CU20160077A7 (es) Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo
IL241184A0 (en) Naphthyridine derivatives and their use as antagonists of alpha-v-beta-6-integrins
HK1217708A1 (zh) 新的雷公藤甲素衍生物及其製備方法和用途
IL243092B (en) New triazolo[d–4,5]pyrimidine histories
HRP20190013T1 (hr) Derivati 1,2-dihidro-3h-pirolo[1,2 -c]imidazol-3-ona i njihova uporaba kao antibakterijska sredstva
IL243525A0 (en) Benzyl-1h-pyrazolo[4,3-b]pyridines and their use
HK1216749A1 (zh) -萘啶衍生物
PL3022210T3 (pl) Nowy pochodne azabenzimidazolu
IL241359A0 (en) Converted indole-5-ol derivatives, preparations containing them and their uses
EP3030239A4 (en) Urea derivatives and uses thereof
SI3027613T1 (sl) Derivati pirolokvinolina kot 5-HT6 antagonisti, postopek priprave in uporabe le-teh
IL240177A (en) Chromium-6-Iloxy-cycloalkanes are conserved and used as drugs
SG11201601135QA (en) 3-substituted cyclopentylamine derivatives
EP3019165A4 (en) Dehydroleucodine derivatives and uses thereof
AU2013902560A0 (en) Heterocyclic compounds and their use